// App-Quantinova.ai

2561 : Pharmacokinetics/pharmacodynamics (PKPD) of blinatumomab in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL).

Researchers

Presenter

  • Min Zhu

Principal Investigators

  • Andrea Kratzer

  • Indrajeet Singh

  • Andreas Wolf

  • Sameer Doshi

  • Jessica Johnson

  • Chris Holland

  • Christian Brandl

Medical Centers

  • Amgen Rockville, Inc., Rockville, MD

  • Amgen Research (Munich) GmbH, Munich, GermanyAmgen Inc., Thousand Oaks, CA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Acute lymphoblastic leukemia

  • Cytokine release syndrome

Biomarkers

  • Breakpoint Cluster Region

  • Twist-related protein 1

Drug/Treatment

  • Blinatumomab

Outcome

  • N/A

Study Design

  • pharmacokinetics

  • pharmacodynamics

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved